The Unsung Vytorin Victim: Primary-Care Marketing
Executive Summary
Not quite three weeks after triggering a medico-commercial earthquake with the ENHANCE trial results, Schering-Plough and Merck have yet to win back three key constituencies: prescribers, patients and investors. The stakes for not doing so are enormous. But more importantly for the industry as a whole, ENHANCE is the latest and strongest sign that the cornerstone on which blockbuster franchises are built-simple, compelling and easy-to-verify measures of treatment success--is crumbling in the face of biological complexity. And that means that primary-care success is going to get a lot more expensive.
You may also be interested in...
Blow the Launch -- Doom the Product
A new IMS survey shows that payors are now virtually the most important determinant of marketplace success -- far more important, in most markets, including the US, than sales representatives, who are less influential than they have ever been. Moreover, marketers who can't create a strong market penetration within six months of launch, will almost certainly fail - no matter what they do - to be able to improve the sales curve.
Biomarkers for Psychiatric Drugs: Outlier or Opportunity?
A handful of companies are pursuing predictive genetic tests for evaluating psychiatric drugs. The need is apparent, and an early success could trigger a rapid shift in thinking about the sustainability of building a business around biomarkers in a therapeutic area sometimes considered the least likely to benefit near term from their development. That said, firms in this area--and elsewhere--must be wary of leaning too heavily on pharma companies as supportive partners.
Biomarkers for Psychiatric Drugs: Outlier or Opportunity?
A handful of companies are pursuing predictive genetic tests for evaluating psychiatric drugs. The need is apparent, and an early success could trigger a rapid shift in thinking about the sustainability of building a business around biomarkers in a therapeutic area sometimes considered the least likely to benefit near term from their development. That said, firms in this area--and elsewhere--must be wary of leaning too heavily on pharma companies as supportive partners.